Related Experiment Video
Updated: May 11, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Can enoxaparin reduce thromboembolism related events after primary TKA in Asian patients?
Geon-Hyeong Kim1, Beom-Yong Park, Tae-Yong Bae
1Department of Orthopaedic Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Abstract:
The purpose of this study was to investigate the efficacy and safety of enoxaparin in preventing venous and arterial thromboembolism related events after primary total knee arthroplasty (TKA) in Asian patients. Four hundred twenty nine patients (621 TKAs) did not receive thromboprophylaxis after TKA and 907 patients (1,336 TKAs) received enoxaparin after the procedure. We assessed clinically significant venous and arterial thromboembolism related events and bleeding complications. Total thromboembolism related events occurred in 13 patients (3.03%) without thromboprophylaxis and 17 patients (1.87%) with enoxaparin (P = 0.183). Our study showed that the incidence of clinically significant thromboembolism related events after TKA was very low in Asian patients. Enoxaparin had no benefits in reducing thromboembolism related events in Asian patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Peripheral Artery Disease V: Postoperative Nursing Management
